Institute of Obstetrics, National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare of Russian Federation, Moscow, Russia.
Department of Maternity, Institute of Obstetrics, National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare of Russian Federation, Moscow, Russia.
J Matern Fetal Neonatal Med. 2022 Dec;35(23):4431-4437. doi: 10.1080/14767058.2020.1850683. Epub 2020 Nov 29.
Evaluation of clinical course of COVID-19 during pregnancy and maternal and perinatal outcomes of this pregnancy.
66 women with polymerase chain reaction (PCR) - confirmed SARS-CoV-2 and their 42 neonates were included in the prospective observational study. Demographic, epidemiological, clinical, laboratory and instrumental data of pregnancy, delivery, postpartum period, including pharmacotherapy and neonatal outcomes were analyzed.
15 (22.7%) women were asymptomatic, 25 (38%) had mild disease, while moderate and severe forms were detected in 20 (30.2%) and 6 (9.1%) cases, respectively. Additional oxygenation was required in 6 (9%) cases: 4 (6%) received CPAP therapy and 2 (3%) - mechanical ventilation. Main clinical symptoms were cough (51.5%), anosmia (34.9%), and hyperthermia (33.3%). Laboratory changes included increased levels of lactate dehydrogenase (LDH), creatinine, d-dimer, and C-reactive protein (CRP), anemia, and leukopenia. All pregnant women received low molecular weight heparin and interferon alfa-2b according to the National clinical recommendations. Antimicrobial drugs included Amoxicillin/Clavulanic acid (46%) and macrolides (28%) or carbapenems in severe cases of disease. Spontaneous abortion was reported in 6.1% of cases. Eight preterm (19%) and 34 term deliveries (81%) occurred. The mean weight of neonates was (3283 ± 477) g, 1- and 5-min Apgar score was (7.8 ± 0.6) and (8.7 ± 0.5), respectively. No cases of neonatal COVID-19 infection were reported.
Mostly, the manifestations of COVID-19 were mild. However, 9% of cases were severe, and could contribute to preterm delivery or maternal morbidity. Main predictors of severe COVID-19 course in pregnant women were a decrease in the levels of erythrocytes and lymphocytes and increase in the levels of alanine aminotransferase and CRP. Elimination of the virus in pregnant women required more time due to altered immunity. No evidence of vertical transmission during pregnancy and delivery was found. However, the possibility of this cannot be excluded.
评估 COVID-19 孕妇的临床病程和母婴围生期结局。
66 名聚合酶链反应(PCR)确诊的 SARS-CoV-2 孕妇及其 42 名新生儿纳入前瞻性观察研究。分析妊娠、分娩、产后期间的人口统计学、流行病学、临床、实验室和仪器数据,包括药物治疗和新生儿结局。
15 例(22.7%)孕妇无症状,25 例(38%)为轻症,20 例(30.2%)和 6 例(9.1%)为中重度。6 例(9%)需要额外吸氧:4 例(6%)接受 CPAP 治疗,2 例(3%)接受机械通气。主要临床症状为咳嗽(51.5%)、嗅觉丧失(34.9%)和发热(33.3%)。实验室检查结果包括乳酸脱氢酶(LDH)、肌酐、D-二聚体和 C 反应蛋白(CRP)水平升高、贫血和白细胞减少。所有孕妇均根据国家临床建议接受低分子肝素和干扰素 alfa-2b 治疗。抗菌药物包括阿莫西林/克拉维酸(46%)和大环内酯类(28%)或疾病严重时使用碳青霉烯类。报告了 6.1%的自然流产病例。8 例早产(19%)和 34 例足月分娩(81%)。新生儿平均体重(3283±477)g,1 分钟和 5 分钟 Apgar 评分分别为(7.8±0.6)和(8.7±0.5)。未报告新生儿 COVID-19 感染病例。
COVID-19 的表现多为轻症。然而,9%的病例为重症,可能导致早产或产妇发病率增加。孕妇重症 COVID-19 病程的主要预测因素是红细胞和淋巴细胞水平下降,丙氨酸氨基转移酶和 CRP 水平升高。由于免疫改变,孕妇清除病毒需要更长的时间。未发现妊娠和分娩期间存在垂直传播的证据。然而,不能排除这种可能性。